Oxford Nanopore Technologies Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere.
The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis.
The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins.
The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments.
With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries!
We are looking for an experienced individual to join our Biologics QC team as a QC Analyst. This role supports the day to day batch release testing of production materials.
The Details...
The successful candidate will support batch release testing of production materials ensuring batch records are correctly followed, incoming materials are successfully logged and stored and relevant process partners are updated on progress. This role will also involve keeping JIRA tickets up to date.
Other responsibilities include
What We're Looking For...
We'll expect you to have some relevant analytical experience ideally in a medical device or pharmaceutical industry. You should have a working knowledge of data analysis/statistical methods and be familiar with continuous improvement methodologies as well as GMP and GLP. We're looking for someone who has a good eye for detail as well as being a strong communicator.
This role will suit someone who is quality and process driven, team orientated, responsive to customer needs and who wants to influence change positively and effectively. A BSc or equivalent is required.
We offer outstanding benefits to include an attractive bonus, generous pension contributions, private healthcare and an excellent starting salary.
If you are looking to utilise your skills to really make a difference to humankind, then consider joining our team and apply today!
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-JC1
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
